known for their activities in regulating transcription, translation, and mRNA splicing. The longterm goal is to determine whether selective targeting of YB-1-dependent NF-kB-activitation is a therapeutic option
in cancer. Preliminary data from the Ybx1 knockout mice are encouraging. First, longterm survival of the whole body Ybx1 knockout mice appears to be unaffected by the loss of YB-1. Secondly, stem cell proliferation and hematopoietic reconstitution are normal in knockouts. Therefore, we should be able to therapeutically targeted YB-1 without adverse side effects .
Kooperationen im Projekt
Leipziger Str. 44
Tel.:+49 391 6724703